Once-Daily Plazomicin for Complicated Urinary Tract Infections

The New England Journal of Medicine
Florian M WagenlehnerEPIC Study Group

Abstract

The increasing multidrug resistance among gram-negative uropathogens necessitates new treatments for serious infections. Plazomicin is an aminoglycoside with bactericidal activity against multidrug-resistant (including carbapenem-resistant) Enterobacteriaceae. We randomly assigned 609 patients with complicated urinary tract infections (UTIs), including acute pyelonephritis, in a 1:1 ratio to receive intravenous plazomicin (15 mg per kilogram of body weight once daily) or meropenem (1 g every 8 hours), with optional oral step-down therapy after at least 4 days of intravenous therapy, for a total of 7 to 10 days of therapy. The primary objective was to show the noninferiority of plazomicin to meropenem in the treatment of complicated UTIs, including acute pyelonephritis, with a noninferiority margin of 15 percentage points. The primary end points were composite cure (clinical cure and microbiologic eradication) at day 5 and at the test-of-cure visit (15 to 19 days after initiation of therapy) in the microbiologic modified intention-to-treat population. Plazomicin was noninferior to meropenem with respect to the primary efficacy end points. At day 5, composite cure was observed in 88.0% of the patients (168 of 191 patients) in the...Continue Reading

References

Jan 1, 1976·Nephron·D W Cockcroft, M H Gault
May 1, 1999·Antimicrobial Agents and Chemotherapy·M P Mingeot-Leclercq, P M Tulkens
Sep 24, 2005·Journal of the American Society of Nephrology : JASN·Glenn M ChertowDavid W Bates
Apr 4, 2008·Kidney International·C Y HsuA S Go
Jan 31, 2009·The New England Journal of Medicine·Cesar A Arias, Barbara E Murray
Feb 27, 2009·Journal of the American Society of Nephrology : JASN·Sushrut S Waikar, Joseph V Bonventre
Feb 23, 2010·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Thomas M HootonUNKNOWN Infectious Diseases Society of America
Sep 2, 2010·Antimicrobial Agents and Chemotherapy·James B AggenHeinz E Moser
Jul 29, 2011·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·A-P MagiorakosD L Monnet
Sep 28, 2013·World Journal of Urology·Jesse D SammonQuoc-Dien Trinh
Feb 4, 2014·Infectious Disease Clinics of North America·Betsy Foxman
Jun 18, 2016·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Florian M WagenlehnerLeanne B Gasink
Oct 8, 2016·Postgraduate Medicine·Mazen S BaderAnnie A Brooks
May 23, 2017·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Emily S SpivakUNKNOWN Management of Urinary Tract Infections Medication Use Evaluation Group
Jan 4, 2018·The New England Journal of Medicine·James R Johnson, Thomas A Russo
Feb 21, 2019·The New England Journal of Medicine·James A McKinnellUNKNOWN CARE Study Group

❮ Previous
Next ❯

Citations

Jan 24, 2019·Antimicrobial Agents and Chemotherapy·Michael TrangChristopher M Rubino
Jul 23, 2019·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Louis D Saravolatz, Gary E Stein
Feb 21, 2019·The New England Journal of Medicine·James A McKinnellUNKNOWN CARE Study Group
Dec 5, 2019·Expert Review of Anti-infective Therapy·Nicola PetrosilloFabrizio Taglietti
Dec 14, 2019·Current Opinion in Infectious Diseases·David L PatersonPatrick N A Harris
Aug 2, 2019·Current Opinion in Critical Care·Carlota GudiolJordi Carratalà
Dec 25, 2019·Journal of the Pediatric Infectious Diseases Society·Kathleen ChiotosPranita D Tamma
Apr 28, 2020·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Dafna YahavDaniel Shepshelovich
Oct 31, 2019·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Hung-Jen Tang, Chih-Cheng Lai
Sep 12, 2020·Expert Opinion on Pharmacotherapy·Matteo BassettiDaniele Roberto Giacobbe
May 2, 2019·Frontiers in Medicine·Matteo BassettiDaniele Roberto Giacobbe
Oct 9, 2019·Expert Opinion on Emerging Drugs·Matteo BassettiMark Wilcox
Sep 22, 2020·Therapeutic Advances in Infectious Disease·Justin A Clark, David S Burgess
Mar 10, 2019·Nature Reviews. Urology·Annette Fenner
Nov 15, 2019·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Yohei Doi
Apr 23, 2020·Expert Review of Anti-infective Therapy·Anastasia BilinskayaJoseph L Kuti
Jul 28, 2020·Expert Opinion on Pharmacotherapy·Mohamad MoussaAthanasios Papatsoris
May 1, 2020·Open Forum Infectious Diseases·Sean Moss, Helen W Boucher
Aug 28, 2020·Nature Reviews. Urology·Florian M E WagenlehnerZafer Tandogdu
Feb 21, 2019·The New England Journal of Medicine·Edward CoxLindsey Baden
Mar 12, 2020·Intensive Care Medicine·Ignacio Martin-LoechesGaryphallia Poulakou
Feb 13, 2020·Medizinische Klinik, Intensivmedizin und Notfallmedizin·M Kächele, F Keller
May 15, 2020·Clinical Microbiology Reviews·David M P De OliveiraMark J Walker
Jun 4, 2020·Therapeutic Advances in Infectious Disease·Matteo Bassetti, Maddalena Peghin
Oct 23, 2020·Expert Opinion on Pharmacotherapy·Lauren M GroftEmily L Heil
Jul 10, 2019·Journal of Molecular Biology·Timothy A Wencewicz
Feb 4, 2021·The Journal of Antimicrobial Chemotherapy·Ursula TheuretzbacherEvelina Tacconelli
Aug 20, 2019·Indian Journal of Medical Microbiology·Balaji VeeraraghavanBalasubramanian Sundaram
Jan 1, 2019·Indian Journal of Medical Microbiology·Balaji VeeraraghavanBalasubramanian Sundaram
Feb 18, 2021·Expert Review of Anti-infective Therapy·Alessandro RussoMatteo Bassetti
Mar 20, 2021·Open Forum Infectious Diseases·Simon PortsmouthGlenn Tillotson
Apr 4, 2021·Microorganisms·Corneliu Ovidiu VrancianuMariana Carmen Chifiriuc
Apr 4, 2021·Journal of Clinical Medicine·Erlangga YusufMireille van Westreenen
Oct 20, 2020·Frontiers in Immunology·Elisavet Stavropoulou, Eugenia Bezirtzoglou
Apr 8, 2021·Expert Opinion on Pharmacotherapy·Joseph P LynchGeorge G Zhanel

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

© 2022 Meta ULC. All rights reserved